Effect of modulation of epithelial-mesenchymal transition regulators Snail1 and Snail2 on cancer cell radiosensitivity by targeting of the cell cycle, cell apoptosis and cell migration/invasion
- PMID: 30655734
- PMCID: PMC6313178
- DOI: 10.3892/ol.2018.9636
Effect of modulation of epithelial-mesenchymal transition regulators Snail1 and Snail2 on cancer cell radiosensitivity by targeting of the cell cycle, cell apoptosis and cell migration/invasion
Abstract
Cancer is one of the leading causes of cancer-associated mortality worldwide. Several strategies of treatment, including radiotherapy, have been developed and used to treat this disease. However, post-treatment metastasis and resistance to treatment are two major causes for the limited effectiveness of radiotherapy in cancer patients. Epithelial-mesenchymal transition (EMT) is regulated by SNAIL family transcription factors, including Snail1 and Snail2 (Slug), and serves important roles in progression and cancer resistance to treatment. Snail1 and Slug also have been shown to be implicated in cancer treatment resistance. For resolving the resistance to treatment problems, combining the modulation of gene expression with radiotherapy is a novel strategy to treat patients with cancer. The present review focuses on the effect of Snail1 and Slug on cancer radiosensitivity by targeting cell apoptosis, the cell cycle and cell migration/invasion.
Keywords: Snail1; Snail2; cancer radiosensitivity; cell apoptosis; cell cycle; cell invasion; cell migration.
Figures
References
-
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. International Agency for Research on Cancer. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. [Dec;Dec;2013 ];IARC CancerBase No.11.Globocan.iarc.fr.
-
- World Health Organization. Health Statistics and Information Systems. Database.who.int/healthinfo/mortality_data/en/ [Nov 6;2014 ];WHO Mortality.
-
- Clifton K, Gutierrez-Barrera A, Ma J, Bassett R, Jr, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018;170:101–109. doi: 10.1007/s10549-018-4727-9. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials